Form 8-K SUPERNUS PHARMACEUTICALS For: Jun 18

Thu, 18 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260618/26666944.html

Form 8-K SUPERNUS PHARMACEUTICALS For: Jun 18

Thu, 18 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260618/26666944.html

Supernus names MERGE as agency of record for its CNS portfolio

Wed, 17 Jun 2026 10:15:10 -0400

Supernus Pharmaceuticals (Nasdaq: SUPN) has expanded its partnership with marketing and technology agency MERGE, naming the firm as its Agency of Record for its central nervous system portfolio, according to a press release.

The agreement extends MERGE's existing relationship with Supernus beyond the company's Parkinson's disease portfolio to include QELBREE® (viloxazine extended-release capsules), a non-stimulant treatment for ADHD. MERGE will also assume oversight of Supernus' digital ecosystem, including website development and CRM operations.

MERGE will continue supporting Supernus' Parkinson's disease brands: APOKYN® (apomorphine hydrochloride), GOCOVRI® (amantadine extended-release capsules), and ONAPGO™ (apomorphine hydrochloride). The agency will lead omnichannel marketing strategy across the portfolio

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

Wed, 17 Jun 2026 10:15:00 -0400

Engagement Includes CNS Portfolio and Digital Ecosystem

CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- MERGE announces its selection as the Agency of Record (AOR) for Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dynamic biopharmaceutical company dedicated to developing cutting-edge treatments for central nervous system (CNS) diseases.

With AI rapidly reshaping the medical marketing landscape, Supernus is moving to embrace a future where human creativity meets the science of data and technology. This expanded partnership, which unifies Supernus’ digital marketing and technology platforms, is designed to leverage MERGE's core philosophy—building a blueprint for human-AI collaboration—to redefine healthcare

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

Wed, 17 Jun 2026 10:15:00 -0400

Engagement Includes CNS Portfolio and Digital Ecosystem

Supernus Pharmaceuticals to Participate in June Investor Conferences

Wed, 27 May 2026 16:30:00 -0400

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences:

2026 Jefferies Global Healthcare Conference

Date:
Fireside chat:
Place:
Webcast Link:

Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New

Supernus Pharmaceuticals to Participate in June Investor Conferences

Wed, 27 May 2026 16:30:00 -0400

2026 Jefferies Global Healthcare Conference

Date:
Fireside chat:
Place:
Webcast Link:

Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New

Supernus Pharmaceuticals to Participate in June Investor Conferences

Wed, 27 May 2026 16:30:00 -0400

2026 Jefferies Global Healthcare Conference

Date:
Fireside chat:
Place:
Webcast Link:

Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New

Supernus Pharmaceuticals to Participate in June Investor Conferences

Wed, 27 May 2026 16:30:00 -0400

2026 Jefferies Global Healthcare Conference

Date:
Fireside chat:
Place:
Webcast Link:

Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New

Form 8-K SUPERNUS PHARMACEUTICALS For: May 17

Wed, 20 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260520/26529021.html

Form 8-K SUPERNUS PHARMACEUTICALS For: May 17

Wed, 20 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260520/26529021.html

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Wed, 06 May 2026 17:00:00 -0400

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.

Investors interested in arranging a meeting with company management during the conference should contact the Bank of

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Wed, 06 May 2026 17:00:00 -0400

Investors interested in arranging a meeting with company management during the conference should contact the Bank of

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Wed, 06 May 2026 17:00:00 -0400

Investors interested in arranging a meeting with company management during the conference should contact the Bank of

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Wed, 06 May 2026 17:00:00 -0400

Investors interested in arranging a meeting with company management during the conference should contact the Bank of

Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31

Tue, 05 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260505/26435042.html

Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31

Tue, 05 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260505/26435042.html

Form 8-K SUPERNUS PHARMACEUTICALS For: May 05

Tue, 05 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260505/26434738.html

Form 8-K SUPERNUS PHARMACEUTICALS For: May 05

Tue, 05 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260505/26434738.html

Supernus Announces First Quarter 2026 Financial Results

Tue, 05 May 2026 16:05:00 -0400

Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.
Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree^® and GOCOVRI^®, and the addition of sales from ZURZUVAE^® and ONAPGO™.
Regulatory submission to the FDA for second supplier for ONAPGO expected in third quarter 2026, with potential approval by mid-year 2027.
The Company reiterates

Supernus Announces First Quarter 2026 Financial Results

Tue, 05 May 2026 16:05:00 -0400

Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.
Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree^® and GOCOVRI^®, and the addition of sales from ZURZUVAE^® and ONAPGO™.
Regulatory submission to the FDA for second supplier for ONAPGO expected in third quarter 2026, with potential approval by mid-year 2027.
The Company reiterates

Form ARS SUPERNUS PHARMACEUTICALS For: Dec 31

Thu, 30 Apr 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260430/26409953.html

Form ARS SUPERNUS PHARMACEUTICALS For: Dec 31

Thu, 30 Apr 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260430/26409953.html

Form DEFA14A SUPERNUS PHARMACEUTICALS

Thu, 30 Apr 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260430/26409917.html

Form DEFA14A SUPERNUS PHARMACEUTICALS

Thu, 30 Apr 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260430/26409917.html

StreetInsider.com News Articles

Form 8-K SUPERNUS PHARMACEUTICALS For: Jun 18

Form 8-K SUPERNUS PHARMACEUTICALS For: Jun 18

Supernus names MERGE as agency of record for its CNS portfolio

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

Supernus Pharmaceuticals to Participate in June Investor Conferences

Supernus Pharmaceuticals to Participate in June Investor Conferences

Supernus Pharmaceuticals to Participate in June Investor Conferences

Supernus Pharmaceuticals to Participate in June Investor Conferences

Form 8-K SUPERNUS PHARMACEUTICALS For: May 17

Form 8-K SUPERNUS PHARMACEUTICALS For: May 17

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31

Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31

Form 8-K SUPERNUS PHARMACEUTICALS For: May 05

Form 8-K SUPERNUS PHARMACEUTICALS For: May 05

Supernus Announces First Quarter 2026 Financial Results

Supernus Announces First Quarter 2026 Financial Results

Form ARS SUPERNUS PHARMACEUTICALS For: Dec 31

Form ARS SUPERNUS PHARMACEUTICALS For: Dec 31

Form DEFA14A SUPERNUS PHARMACEUTICALS

Form DEFA14A SUPERNUS PHARMACEUTICALS